Back to Search Start Over

Non-invasive alloimmune risk stratification of long-term liver transplant recipients.

Authors :
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service de chirurgie et transplantation abdominale
Vionnet, Julien
Miquel, Rosa
Abraldes, Juan G
Wall, Jurate
Kodela, Elisavet
Lozano, Juan-Jose
Ruiz, Pablo
Navasa, Miguel
Marshall, Aileen
Nevens, Frederik
Gelson, Will
Leithead, Joanna
Masson, Steven
Jaeckel, Elmar
Taubert, Richard
Tachtatzis, Phaedra
Eurich, Dennis
Simpson, Kenneth J
Bonaccorsi Riani, Eliano
Feng, Sandy
Bucuvalas, John
Ferguson, James
Quaglia, Alberto
Sidorova, Julia
Elstad, Maria
Douiri, Abdel
Sánchez-Fueyo, Alberto
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service de chirurgie et transplantation abdominale
Vionnet, Julien
Miquel, Rosa
Abraldes, Juan G
Wall, Jurate
Kodela, Elisavet
Lozano, Juan-Jose
Ruiz, Pablo
Navasa, Miguel
Marshall, Aileen
Nevens, Frederik
Gelson, Will
Leithead, Joanna
Masson, Steven
Jaeckel, Elmar
Taubert, Richard
Tachtatzis, Phaedra
Eurich, Dennis
Simpson, Kenneth J
Bonaccorsi Riani, Eliano
Feng, Sandy
Bucuvalas, John
Ferguson, James
Quaglia, Alberto
Sidorova, Julia
Elstad, Maria
Douiri, Abdel
Sánchez-Fueyo, Alberto
Source :
Journal of Hepatology, Vol. 75, no. 6, p. 1409-1419 (2021)
Publication Year :
2021

Abstract

Management of long-term immunosuppression following liver transplantation (LT) remains empirical. Surveillance liver biopsies in combination with transcriptional profiling could overcome this challenge by identifying recipients with active alloimmune-mediated liver damage despite normal liver tests, but has low applicability. Our aim was to investigate the utility of non-invasive tools in stratifying stable long-term LT recipients according to their immunological risk and need for immunosuppression. We conducted a cross-sectional multicentre study of 190 adult liver recipients assessed to determine their eligibility to participate in an immunosuppression withdrawal trial. Patients had stable liver allograft function and had been transplanted for non-autoimmune non-replicative viral liver disease >3 years before inclusion. We performed histological, immunogenetic and serological studies and measured the intrahepatic transcript levels of an 11-gene classifier highly specific for T cell-mediated rejection (TCMR). 36% patients harboured clinically-silent fibro-inflammatory liver lesions, which were scored as moderate-to-severe in 22%. The severity of liver allograft damage was positively associated with TCMR-related transcripts, class II donor-specific antibodies (DSA), ALT/AST and liver stiffness measurements (LSM), and negatively correlated with serum creatinine and tacrolimus trough levels. Liver biopsies were stratified according to their TCMR transcript levels using a cut-off derived from biopsies with clinically-significant TCMR. Two multivariable prediction models, integrating ALT/LSM or ALT/class II DSA, respectively, had a high discriminative capacity in classifying patients with or without alloimmune damage. The latter model had a good performance in an independent cohort of 156 liver biopsies obtained from paediatric liver recipients with similar inclusion/exclusion criteria. ALT, class II DSA and LSM are valuable tools to non-invasively identify stable LT re

Details

Database :
OAIster
Journal :
Journal of Hepatology, Vol. 75, no. 6, p. 1409-1419 (2021)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1288278171
Document Type :
Electronic Resource